Study of BEBT-908 for a rare subtype of acute lymphoblastic leukemia
This study tests whether the drug BEBT-908 can help people with a specific genetic change (MEF2D rearrangement) in their leukemia that has either come back, not responded to treatment, or left behind a small amount of disease. It aims to see how safe and effective the drug is in treating this subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be aged 14 to 75 years old
- Have B-cell acute lymphoblastic leukemia with a specific genetic change called MEF2D rearrangement
- Your leukemia has either returned, not responded to treatment, or you still have a small amount of disease after treatment
- Be generally well enough to care for yourself (ECOG score 0-2) and have adequate organ function
- Not have active leukemia in the central nervous system (brain or spinal cord)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BEBT-908 combined with chemotherapy for adults with a specific type of acute lymphoblastic leukemia (ALL) who are in remission but still have small amounts of cancer cells (MRD positive). The goal is to see if this combination can get rid of those remaining cells and reduce the risk of relapse.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This study tests a new drug (BEBT-908) combined with standard chemotherapy for people with untreated peripheral T-cell lymphoma. The goal is to see if the combination helps shrink tumors.
Hear when a new B-cell Precursor Acute Lymphoblastic Leukemia (ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.